Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain

VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low Doses PHILADELPHIA, Oct. 23, 2015 -- (Healthcare Sales & Marketing Network) -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advan... Biopharmaceuticals, FDAIroko Pharmaceuticals, VIVLODEX, meloxicam, NSAID, osteoarthritis

http://salesandmarketingnetwork.com/news_release.php?ID=2040326

Source: HSMN NewsFeed - October 23, 2015 Category: Pharmaceuticals Source Type: news